These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 19398955)

  • 21. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
    Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
    J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.
    Ghiorzo P; Villaggio B; Sementa AR; Hansson J; Platz A; Nicoló G; Spina B; Canepa M; Palmer JM; Hayward NK; Bianchi-Scarrà G
    Hum Pathol; 2004 Jan; 35(1):25-33. PubMed ID: 14745721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decoding the Molecular Mechanisms of BRAF
    Liang WZ; Liu YX; Xu DD; Jiang WJ; Ran RS
    Biomed Environ Sci; 2024 Jul; 37(7):774-784. PubMed ID: 39198241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF
    McNeal AS; Belote RL; Zeng H; Urquijo M; Barker K; Torres R; Curtin M; Shain AH; Andtbacka RH; Holmen S; Lum DH; McCalmont TH; VanBrocklin MW; Grossman D; Wei ML; Lang UE; Judson-Torres RL
    Elife; 2021 Nov; 10():. PubMed ID: 34812139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of ARF sensitizes transgenic BRAFV600E mice to UV-induced melanoma via suppression of XPC.
    Luo C; Sheng J; Hu MG; Haluska FG; Cui R; Xu Z; Tsichlis PN; Hu GF; Hinds PW
    Cancer Res; 2013 Jul; 73(14):4337-48. PubMed ID: 23650282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The plasma membrane Ca
    Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
    Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.
    Tschandl P; Berghoff AS; Preusser M; Pammer J; Pehamberger H; Kittler H
    Br J Dermatol; 2016 Feb; 174(2):364-70. PubMed ID: 26613644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
    Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
    J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
    Hay R; MacRae E; Barber D; Khalil M; Demetrick DJ
    Arch Pathol Lab Med; 2007 Sep; 131(9):1361-7. PubMed ID: 17824790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes.
    Ruiz-Vega R; Chen CF; Razzak E; Vasudeva P; Krasieva TB; Shiu J; Caldwell MG; Yan H; Lowengrub J; Ganesan AK; Lander AD
    Elife; 2020 Oct; 9():. PubMed ID: 33047672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated Hgf-Met Signaling Cooperates with Oncogenic BRAF to Drive Primary Cutaneous Melanomas and Angiotropic Lung Metastases in Mice.
    Braun AD; Mengoni M; Bonifatius S; Tüting T; Gaffal E
    J Invest Dermatol; 2020 Jul; 140(7):1410-1417.e2. PubMed ID: 31972251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.
    Terzian T; Torchia EC; Dai D; Robinson SE; Murao K; Stiegmann RA; Gonzalez V; Boyle GM; Powell MB; Pollock PM; Lozano G; Robinson WA; Roop DR; Box NF
    Pigment Cell Melanoma Res; 2010 Dec; 23(6):781-94. PubMed ID: 20849464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation.
    Zeng H; Jorapur A; Shain AH; Lang UE; Torres R; Zhang Y; McNeal AS; Botton T; Lin J; Donne M; Bastian IN; Yu R; North JP; Pincus L; Ruben BS; Joseph NM; Yeh I; Bastian BC; Judson RL
    Cancer Cell; 2018 Jul; 34(1):56-68.e9. PubMed ID: 29990501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
    Zimmer L; Hillen U; Livingstone E; Lacouture ME; Busam K; Carvajal RD; Egberts F; Hauschild A; Kashani-Sabet M; Goldinger SM; Dummer R; Long GV; McArthur G; Scherag A; Sucker A; Schadendorf D
    J Clin Oncol; 2012 Jul; 30(19):2375-83. PubMed ID: 22614973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of the BRAF gene in benign and malignant melanocytic lesions.
    Yazdi AS; Palmedo G; Flaig MJ; Puchta U; Reckwerth A; Rütten A; Mentzel T; Hügel H; Hantschke M; Schmid-Wendtner MH; Kutzner H; Sander CA
    J Invest Dermatol; 2003 Nov; 121(5):1160-2. PubMed ID: 14708620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
    Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
    Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
    Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.